The Global Leader in Relapsed/Refractory AL Amyloidosis

Changing the Sentence Forever

"Are there any options left for AL Amyloidosis?" Because of Immix, the answer is finally: "Yes."

We've found a breakthrough to change that hopeless sentence.
Our mission is simple: Create medicines that work
without destroying the person.

Discover the BreakthroughAccess Clinical Results
The Stark Reality

The Current Paradigm is Failing

When AL Amyloidosis Comes Back, There's Nowhere to Turn

There are no FDA-approved drugs for relapsed/refractory AL amyloidosis. Doctors are forced
to recycle old drug combinations, knowing they'll fail again. Current treatments produce
a devastating 0-10% complete response rate.
For patients with this rare, deadly disease—where toxic proteins attack vital organs, especially the heart—this isn't just a statistic. It's a death sentence.

Introducing NXC-201

We Re-Engineer the Immune System
to Fight for You Again

NXC-201 is a revolutionary one-time CAR-T therapy that harnesses the power of your own immune system to eliminate the diseased cells causing AL amyloidosis, targeting the root cause.

Through advanced engineering, we've created a treatment that's both extraordinarily effective and remarkably safe, addressing the critical limitations that have made other therapies impossible for this vulnerable patient population.

Normalizes Disease Within Days

Diseased light chains return to normal levels within a median of just 7 days after treatment, giving your organs the chance to heal.

Single Infusion, Durable Response

Unlike ongoing treatment regimens, NXC-201 requires just one infusion. Your re-engineered immune cells continue working long-term.

Designed for Safety

Zero neurotoxicity. Minimal side effects. The shortest cytokine release syndrome duration of any BCMA CAR-T, critical for protecting
vulnerable hearts.

See How It Works
ASCO 2025 Data

Extraordinary Results in Clinical Trials

Unprecedented outcomes in one of medicine's most challenging diseases

Our U.S. NEXICART-2 registrational trial is delivering results that are transforming the treatment landscape for relapsed/refractory AL amyloidosis.

10/10

Patients
Normalized disease markers

7 Days

Median time
To normalization

0%

Neurotoxicity
Across all patients

1 Day

Median CRS
vs. 4-8 days for other CAR-Ts

"An early and deep hematologic response has been found to lead to significantly prolonged survival."

Vaishali Sanchorawala, M.D.
Professor of Hematology and Oncology
Director, Amyloidosis Center at Boston University School of Medicine

The Science Behind the Breakthrough

Sterically-Optimized Engineering
Makes the Difference

All BCMA CAR-Ts are not created equal

NXC-201 features three proprietary modifications that deliver "digital" signaling precision while dramatically reducing side effects, particularly critical for AL amyloidosis patients whose primary cause of mortality is heart failure.

Innovation 1

Optimized CD3ζγ Signaling

Delivers precise "digital" intracellular signaling, reducing non-specific activation and cytokine release.
Innovation 2

Enhanced CD8 Hinge

Acts as a "digital filter" preventing inappropriate T-cell activation and further reducing CRS risk.
Innovation 3

COBRA Binder Technology

Improves plasma cell binding and expression while maintaining flexibility for optimal function.

4-8x

Shorter CRS Duration

NXC-201's median 1-day CRS duration vs. 4-8 days for other BCMA CAR-Ts makes it uniquely suitable for treating vulnerable AL amyloidosis patients.

Explore the Science

Beyond AL Amyloidosis: A Platform Built to Transform Multiple Diseases

While our immediate focus is establishing NXC-201 as the standard of care for relapsed/refractory AL amyloidosis, our breakthrough represents far more than a single-disease solution.

NXC-201 targets plasma cells, the antibody factories of the immune system. Success in AL amyloidosis validates our approach and opens the door to treating dozens of antibody-mediated diseases affecting millions of patients worldwide.

Neurology

  • Myasthenia Gravis
  • NMO Spectrum Disorder

Rheumatology

  • Systemic Lupus Erythematosus
  • Rheumatoid Arthritis

Hematology

  • Immune Thrombocytopenia

Neurology

  • Myasthenia Gravis
  • NMO Spectrum Disorder

$10B+

Total Addressable Market

Across plasma cell-driven immune diseases, with AL amyloidosis alone representing $1.4-2.8 billion in annual sales potential

View Our Pipeline

We Are on the Brink of
Turning Despair Into Hope

Our progress is accelerating toward commercial launch

2023-2024

  • FDA Orphan Drug & RMAT Designations secured
  • NEXICART-1 ex-U.S. trial: 75% complete response rate
  • Published in Journal of Clinical Oncology
  • Mentioned in NEJM AL Amyloidosis review

Q2 2025

  • ASCO oral presentation: 70% complete response rate in U.S. trial
  • First 10 patients demonstrate consistent efficacy and safety

Q3-Q4 2025

  • Expanding to additional academic trial sites
  • Phase 1 final readout

2026

  • Trial enrollment completion (Q1)
  • BLA submission to FDA (Q2)
  • Commercial launch (Late 2026)

For Patients

If you've been diagnosed with relapsed or refractory AL amyloidosis, our clinical trial may offer hope. Learn about eligibility and enrollment.
Check Trial Eligibility

For Physicians

We're expanding our network of trial sites. Learn how to refer eligible patients or establish your center as a trial site.
Become a Trial Site

For Investors

Late-stage biotech with breakthrough clinical data, clear regulatory path, and platform potential worth billions.
Explore Investment Opportunity

We Are on the Brink of
Turning Despair Into Hope

Billions in market potential. Millions of lives changed. This is just the beginning.
Become a PartnerJoin Our TeamGet Updates